uniQure released 48-month data for its Huntington's disease drug AMT-130 showing a 44% slowing of disease progression, down from 75% at 36 months. This weaker result caused the stock to drop 37.3% in one day. The company had already submitted an FDA application based on the earlier 36-month data. A law firm is investigating possible securities law violations by uniQure and its management related to these disclosures.
The uniQure N.V. investigation news comes as the health sector on Pluang shows broad weakness, with only 29 of 128 US health stocks rising today. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 03:41 WIB: HRTX (Heron Therapeutics Inc) dropped 5.32% to USD 0.39 with a typical hold time of 36 days and order activity skewed 61% sell; NUWE (Nuwellis Inc) fell 5.27% to USD 0.64 with a 27-day hold time and 64% buy orders; TXG (10X Genomics Inc) declined 4.52% to USD 71.79 with a 92-day hold time and 100% buy orders.
ZenaTech announced a 27.1% organic revenue growth in its Drone as a Service (DaaS) operations in 2026, driven by integrating AI and drones into surveying and inspection workflows. The company expects Q3 2026 revenues between C$13.4 million and C$14.8...
Nvidia CEO Jensen Huang has reaffirmed his long-standing forecast that global spending on AI infrastructure will surge to between $3 trillion and $4 trillion by 2030. This projection highlights the massive growth potential in the AI sector, driven by...
Targa Resources Corp. announced a quarterly cash dividend of $1.25 per common share for Q3 2026, payable on November 17, 2026, to shareholders of record as of October 30, 2026. The company will release its Q3 2026 financial results before market open...
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
Goldman Sachs reported strong third-quarter results, with an 18.7% return on equity (ROE) and earnings per share (EPS) of $17, surpassing expectations. The performance was boosted by momentum in its Global Banking & Markets and Asset & Wealth Managem...
